TerminatedPhase 2NCT05971602
Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
Studying Primary pulmonary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gates Medical Research Institute
- Principal Investigator
- Gates MRIGates Medical Research Institute
- Intervention
- Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)(drug)
- Enrollment
- 93 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2023 – 2025
Study locations (13)
- Tropical Disease Foundation, Makati, Philippines
- Lung Center of the Philippines, Quezon City, Philippines
- Silang Specialist Medical Center, Silang, Philippines
- Bio-Medical Research Institute; Faculty of Medicine and Health Sciences, Stellenbosch University; Tygerberg Medical Campus, Cape Town, South Africa
- TASK - Central (Brooklyn), Cape Town, South Africa
- UCT (Cape Town); General Medicine & Global Health (GMGH); Hatter Heart Research Institute, Cape Town, South Africa
- UCT South African Tuberculosis Vaccine Initiative (SATVI), Cape Town, South Africa
- University of Cape Town (UCT) Lung Institute, Cape Town, South Africa
- CHRU - Durban, Durban, South Africa
- Synergy Biomed Research Institute, East London, South Africa
- Clinical HIV Research Unit (CHRU) - Johannesburg, Johannesburg, South Africa
- The Aurum Institute (Tembisa CRS), Johannesburg, South Africa
- Perinatal HIV Research Unit (PHRU), Klerksdorp, South Africa
Collaborators
Global Alliance for TB Drug Development · Janssen Pharmaceuticals · Otsuka Pharmaceutical Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05971602 on ClinicalTrials.govOther trials for Primary pulmonary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07517445Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary TuberculosisGates Medical Research Institute
- RECRUITINGPHASE2NCT07525427Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary TuberculosisGates Medical Research Institute
- RECRUITINGNANCT07484490Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in TuberculosisRiphah International University
- RECRUITINGPHASE3NCT07209761A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisOtsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGPHASE2NCT07170800A Phase 2b Clinical Study of JDB0131 Benzenesulfonate TabletsWestVac Biopharma Co., Ltd.
- RECRUITINGPHASE2NCT06192160Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE2NCT06748937A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With EthionamideTASK Applied Science
- ACTIVE NOT RECRUITINGNANCT07186478I-FALMIN Albumin Supplement for Patients With Pulmonary TuberculosisHasanuddin University